📰 Company Expanded Access Program News
Page 3 - Company Expanded Access Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Company Expanded Access Program. Real-time updates on events, politics, business and more.
May 22, 2023
RedHill has elected to terminate RHB-204s U.S. Phase 3 study for Non-tuberculosis Mycobacteria disease due to low accrual rate and plans to shift resources to more rapidly advance RHB-107... | May 22, 2023
May 15, 2023
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has received...
April 28, 2023
Having extinguished all debt and significantly reduced cost-base, RedHill is now focused on late-stage pipeline advancement, in collaboration with U.S. and...
April 11, 2023
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received...
April 3, 2023
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed...
April 3, 2023
RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,500,000 of the Company's American...
March 30, 2023
/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered...
March 16, 2023
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it plans to...
March 9, 2023
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced agreement, with a...
February 28, 2023
The National Institutes of Healths (NIH) Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for testing via their radiation medical...